Fig. 1: Patient flow diagram.
From: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial
CONSORT flow diagram showing participant disposition and data analysis sets, including reasons for discontinuation. Of the 85 participants treated, 75 (88.2%; n = 59 in pegozafermin and n = 16 in placebo) completed treatment. QW, once-weekly; Q2W, once every 2 weeks.
